| Literature DB >> 35619648 |
Hongyu Zhao1, Rufeng Chen2, Dongxue Zheng1, Feng Xiong3, Fan Jia1, Jinyuan Liu2, Lili Zhang1, Nana Zhang2, Shiqin Zhu2, Yongmei Liu1, Linhua Zhao1, Xinmin Liu1.
Abstract
Objective: To analyze the characteristics of the intestinal microbiota of polycystic ovarian syndrome with insulin resistance (PCOS-IR) and explore the possible mechanism of modified Banxia Xiexin Decoction in the treatment of PCOS-IR.Entities:
Keywords: inflammation; insulin resistance; intestinal microbiota; metabolism; modified Banxia Xiexin Decoction; polycystic ovary syndrome
Mesh:
Substances:
Year: 2022 PMID: 35619648 PMCID: PMC9127304 DOI: 10.3389/fcimb.2022.854796
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 6.073
Changes in reproductive, metabolic, and inflammatory factors in all rats.
| Parameters | Control (n = 6) | Model (n = 6) | Treatment (n = 5) |
|---|---|---|---|
| Weight (g) | 224.67 ± 8.29 | 308.83 ± 15.70** | 285.00 ± 17.00# |
| E2 (ng/L) | 44.98 ± 3.85 | 46.74 ± 5.35 | 45.70 ± 1.83 |
| T (ng/ml) | 0.69 ± 0.02 | 1.05 ± 0.14** | 1.17 ± 0.27 |
| FSH (ng/L) | 8.10 (7.51, 9.29) | 8.96 (8.58, 10.61) | 8.75 (8.12, 9.58) |
| LH (ng/L) | 21.47 ± 1.89 | 26.79 ± 5.20 | 27.03 ± 2.26 |
| LH/FSH | 2.60 ± 0.41 | 2.89 ± 0.78 | 3.09 ± 0.44 |
| Glu (mmol/l) | 4.98 ± 0.41 | 6.08 ± 1.00* | 5.92 ± 0.30 |
| FINS (mIU/l) | 20.38 ± 0.83 | 20.02 ± 1.60 | 19.32 ± 0.86 |
| HOMA-IR | 4.51 ± 0.40 | 5.71 ± 0.78 | 5.08 ± 0.32 |
| HOMA-beta | 283.66 (206.35, 385.51) | 141.79 (125.38, 260.29) | 170.47 (139.24, 179.85) |
| LPS (ng/L) | 67.71 ± 2.80 | 79.48 ± 10.14 | 71.39 ± 14.17 |
| TNF-α (pg/ml) | 71.71 ± 9.50 | 79.03 ± 11.31 | 56.28 ± 14.73 |
Data are presented as mean ± SD or as medians with interquartile ranges.
E2, estradiol; T, testosterone; FSH, follicle-stimulating hormone; LH, luteinizing hormone; LH/FSH, the ratio of LH to FSH; Glu, fasting plasma glucose; FINS, fasting plasma insulin; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-beta, homeostasis model assessment for beta-cell function; LPS, lipopolysaccharide; TNF-α, tumor necrosis factor-α.
*p < 0.05, **p < 0.01 for control vs. model group.
#p < 0.05 for model vs. treatment group.
Figure 1Characteristics of reproductive hormones, glucose metabolism, and inflammatory factors.
Figure 2Changes in ovarian histomorphological (H&E stain). (A, B) Control group. (C, D) Model group. (E, F) Treatment group.
Figure 3Diversity of intestinal microbiota community. Z, control group; M, model group; A, treatment group. PCoA, principal coordinate analysis; PLS-DA, partial least squares discriminant analysis. (A) Ace index. (B) Shannon index. (C) PCoA. (D) PLS-DA.*p < 0.05; **p < 0.01.
Figure 4Composition and difference analysis of intestinal microbiota at phylum and genus levels. Z, control group; M, model group; A, treatment group. (A) Percent of community abundance on Phylum level. (B) Percent of community abundance on Genus level. (C) The microbiota proportions’ difference between Group Z and M on Phylum level. (D) The microbiota proportions’ difference between Group M and A on Phylum level. (E) The microbiota proportions’ difference between Group Z and M on Genus level. (F) The microbiota proportions’ difference between Group M and A on Genus level. (G) Cladogram by Lefse analysis. *p < 0.05; **p < 0.01.
Figure 5Predictive functional profiling of microbiota community. Z, control group; M, model group; A, treatment group. (A) COG function classification. (B) KEGG Pathway Level 1. (C) KEGG Pathway Level 3.